Severe neutropenia in cytotoxic therapy

Indication for Lenograstim

Population group: Suitable for both men and women, only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Lenograstim is indicated in adults, adolescents and children aged older than 2 years for the reduction of the duration of severe neutropenia and its associated complications in patients undergoing established cytotoxic therapy associated with a significant incidence of febrile neutropenia.

For this indication, competent medicine agencies globally authorize below treatments:

150 μg/m² once daily

Route of admnistration

Subcutaneous

Defined daily dose

150 - 150 ug per m² of body surface area (BSA)

Dosage regimen

From 150 To 150 ug per m² of body surface area (BSA) once every day

Detailed description

Lenograstim should be administered daily at the recommended dose of 19.2 MIU (150 µg) per m² per day as a subcutaneous injection. The first dose should not be administered less than 24 hours following cytotoxic chemotherapy. Daily administration of lenograstim should continue until the expected nadir has passed and the neutrophil count returns to a stable level compatible with treatment discontinuation, with, if necessary, a maximum of 28 consecutive days of treatment.

A transient increase in neutrophil count may occur within the first 2 days of treatment, however lenograstim treatment should not be stopped, since the subsequent nadir usually occurs earlier and recovers more quickly if treatment continues.

19.2 MIU/m² once daily

Route of admnistration

Subcutaneous

Defined daily dose

19,200,000 - 19,200,000 [iU] per m² of body surface area (BSA)

Dosage regimen

From 19,200,000 To 19,200,000 [iU] per m² of body surface area (BSA) once every day

Detailed description

Lenograstim should be administered daily at the recommended dose of 19.2 MIU (150 µg) per m² per day as a subcutaneous injection. The first dose should not be administered less than 24 hours following cytotoxic chemotherapy. Daily administration of lenograstim should continue until the expected nadir has passed and the neutrophil count returns to a stable level compatible with treatment discontinuation, with, if necessary, a maximum of 28 consecutive days of treatment.

A transient increase in neutrophil count may occur within the first 2 days of treatment, however lenograstim treatment should not be stopped, since the subsequent nadir usually occurs earlier and recovers more quickly if treatment continues.

Active ingredient

Lenograstim belongs to the cytokine group of biologically active proteins which regulate cell differentiation and cell growth. Lenograstim induces a marked increase in peripheral blood neutrophil counts within 24 hours of administration.

Read more about Lenograstim

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner